Table 1.

Patient characteristics and outcomes. (AE, adverse event; DLT, dose-limiting toxicity; TX, treatment, MCL, mantle cell lymphoma, FL, follicular lymphoma; idela, idelalisib; len, lenalidomide, ritux, rituximab; AST, aspartate aminotransferase; ALT, alanine aminotransferase)

Patient ID	Age, Gender	Diagnosis	Cumulative idelalisib dose	Cumulative lenalidomide dose	Cumulative rituximab dose	DLT	Off study for AE	Comments
1-001	53 yo M	MCL	6300mg	300mg	2910mg	YES	YES	Developed fevers and grade 4 AST and ALT elevation on Day 20
1-002	59 yo M	MCL	4300mg	630mg	–	NO	YES	Grade 3 maculopapular rash on Day 15
1-003	66 yo F	MCL, blastoid	3650mg	690mg	–	YES	YES	Grade 3 AST elevation and grade 3 maculopapular rash
2-001	59 yo M	FL	45,800mg	1260mg	3600mg	NO	YES	Grade 3 lung infection
2-002	62 yo F	FL	4950mg	160mg	1088mg	YES	YES	Grade 4 septic shock on Day 17
2-003	47 yo M	FL	5000mg	560mg	2852mg	NO	NO	Had grade 3 maculopapular rash during cycle 1 but resumed treatment with reduction of both idelalisib and lenalidomide
2-004	77 yo F	FL	4650mg	360mg	2864mg	NO	YES	Grade 3 allergic reaction and maculopapular rash during Cycle 1. Rash recurred despite omission and reductions of lenalidomide and idelalisib.
2-005	53 yo F	FL	3000mg	100mg	667mg	YES	YES	Patient developed fevers, facial edema, total body coalescent rash, hypotension 24 hours after rituximab administration. Admitted to ICU and on pressors.
2-006	59 yo M	FL	33,600mg	1260mg	3116mg	NO	NO
2-007	61 yo M	FL	4500mg	150mg	770mg	YES	YES	Grade 3 maculopapular rash and grade 3 lung infection on Day 15
2-008	65 yo M	FL	50,400mg	1050mg	–	NO	NO